Oligodendroglioma: Pathology and molecular biology

Surgical Neurology

Volumn 58, Issue 2, 2002, Pages 111-117

  Engelhard, Herbert H ^a   Stelea, Ana ^a   Cochran, Elizabeth J ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b RUSH UNIVERSITY   (United States)

Author keywords

Brain tumor; Ki 67; Malignant glioma; Molecular biology; Oligodendroglioma; Tumor markers

Indexed keywords

CYCLOOXYGENASE 1; ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; M PROTEIN; MOLECULAR MARKER; PLATELET DERIVED GROWTH FACTOR; PROTEIN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P18; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALLELISM; ARTICLE; ASTROCYTE; ASTROCYTOMA; BOOK; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHROMOSOME 19P; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; ELECTRON MICROSCOPY; EPENDYMOMA; GENETIC MARKER; GLIOMA; HISTOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; MEDICAL LITERATURE; MEDLINE; MOLECULAR BIOLOGY; NEUROEPITHELIOMA; NEUROEPITHELIUM; NEUROPATHOLOGY; OLIGODENDROGLIOMA; PATHOLOGIST; PROGNOSIS; RECURRENT DISEASE; STATISTICAL ANALYSIS; WORLD HEALTH ORGANIZATION;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; HUMANS; KI-67 ANTIGEN; LOSS OF HETEROZYGOSITY; OLIGODENDROGLIOMA; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0036703678     PISSN: 00903019     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-3019(02)00751-6     Document Type: Article

References (55)

1. Bauman G.S., Ino Y., Ueki K., et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys. 48:2000;825-830.
2. Bello M.J., Leone P.E., Vaquero J., et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer. 64:1995;207-210.
3. Bello M.J., Vaquero J., de Campos J.M., et al. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer. 57:1994;172-175.
4. Bortolotto S., Chiado-Piat L., Cavalla P., et al. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer. 88:2000;554-557.
5. Bruner L.M. Neuropathology of malignant gliomas. Semi Oncol. 21:1994;126-138.
6. Burger P.C., Rawlings C.E., Cox E.B., McLendon R.E., Schold S.C. Jr, Bullard D.E. Clinicopathologic correlations in the oligodendroglioma. Cancer. 59:1987;1345-1352.
7. Burger P.C., Scheithauer B.W. Tumors of the Central Nervous System. Atlas of tumor pathology, 3rd series, Fascicle 10. 1994;107-120 Armed Forces Institute of Pathology, Washington, DC.
8. nd edn. 1991;306-324 Churchill Livingstone, New York.
9. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 90:1998;1473-1479.
10. Cenacchi G., Giangaspero A., Cerasoli S., Manetto V., Martinelli G.N. Ultrastructural characterization of oligodendroglial-like cells in central nervous system tumors. Ultrastruct Pathol. 20:1996;537-547.
11. Coons S.W., Johnson P.C. MIB-1/Ki-67 labeling index predicts patient survival for oligodendroglial tumors. J Neuropathol Exp Neurol. 54:1995;440. [Abstract.].
12. Coons S.W., Johnson P.C., Scheithauer B.W., Yates A.J., Pearl D.K. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 79:1997;1381-1393.
13. Coons S.W., Johnson P.C., Pearl D.K. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurg. 41:1997;878-884.
14. Cruz-Sanchez F.F., Rossi M.L., Buller J.R., et al. Oligodendrogliomas a clinical, histological, immunocytochemical and lectin-binding study. Histopathol. 19:1991;361-367.
15. Daumas-Duport C., Varlet P., Tucker M.L., Beuvon F., Cervera P., Chodkiewicz J.P. Oligodendrogliomas. Part I Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol. 34:1997;37-59.
16. Daumas-Duport C., Tucker M.-L., Kolles H., et al. Oligodendrogliomas part II-A new grading system based on morphological and imaging criteria. J Neurooncol. 34:1997;61-78.
17. Dehghani F., Schachenmayr W., Laun A., Korf H.W. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas a study of 89 cases. Acta Neuropathol (Berl). 95:1998;493-504.
18. Deininger M.H., Meyermann R., Trautmann K., et al. Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression. Brain Res. 885:2000;111-116.
19. Di Rocco F., Carroll R.S., Zhang J., Black P.M. Platelet-derived Growth Factor and its receptor expression in human oligodendrogliomas. Neurosurg. 42:1998;341-346.
20. Engelhard H.H., Stelea A.C. Oligodendroglioma clinical features, treatment and prognosis. Surg Neurol. 2002;. in press.
21. Fortin D., Cairncross G.J., Hammond R.R. Oligodendroglioma an appraisal of recent data pertaining to diagnosis and treatment. Neurosurg. 45:1999;1279-1291.
22. Giannini C., Scheithauer B.W., Weaver M.S., et al. Oligodendrogliomas reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol. 60:2001;248-262.
23. Hagel C., Krog B., Laas R., Stavrou D.K. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas. J Exp Clin Cancer Res. 18:1999;305-309.
24. He J., Hoang-Xuan K., Marie Y., et al. P18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia. Neurol. 55:2000;867-869.
25. Heegaard S., Sommer H.M., Broholm H., Broendstrup O. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer. 76:1995;1809-1813.
26. Jeuken J.W.M., Sprenger S.H.E., Wesseling P., et al. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol. 58:1999;606-612.
27. Kleihues P., Cavenee W.K., Pathology and genetics: tumours of the nervous system. In WHO classification of tumours. 2000;56-61 IARC Press, Lyon (France).
28. Korshunov A., Golanov A. The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases. J Neurooncol. 48:2000;13-19.
29. Kraus J.A., Koopmann J., Kaskel P., et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol. 54:1995;91-95.
30. Kros J.M., de Jong A.A.W., van der Kwast Th H. Ultrastructural characterization of transitional cell in oligodendrogliomas. J Neuropathol Exp Neurol. 51:1992;186-193.
31. Kros J.M., Godschalk J.J., Krishnadath K.K., Van Eden C.G. Expression of p53 in oligodendrogliomas. J Pathol. 171:1993;285-290.
32. Kros J.M., Hop W.C., Godschalk J.J., Krishnadath K.K. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer. 78:1996;1107-1113.
33. Liberski P.P. The ultrastructure of oligodendroglioma personal experience and the review of the literature. Folia Neuropathol. 34:1996;206-211.
34. Margain D., Pretti-Viton P., Perez-Castillo A.M., Martini P., Salamon G. Les oligodendrogliomes. Oligodendroglioma. J Neuroradiol. 18:1991;153-160.
35. Miettinen H.E., Jarvinen T.A.H., Kellner U., et al. High topoisomerase II alpha expression associates with high proliferation rate and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol. 26:2000;504-512.
36. Miettinen H., Kononen J., Sallinen P., et al. CDKN2/p16 predicts survival in oligodendrogliomas comparison with astrocytoma. J Neurooncol. 41:1999;205-211.
37. Mork S.J., Halvorsen T.B., Lindegaard K.-F., Eide G.E. Oligodendroglioma histologic evaluation and prognosis. J Neuropathol Exp Neurol. 45:1986;65-78.
38. Ohgaki H., Eibl R.H., Wiestler O.D., et al. p53 mutations in nonastrocytic human brain tumors. Cancer Res. 51:1991;6202-6205.
39. Pavelic J., Hlavka V., Poljak M., Gale N., Pavelic K. p53 immunoreactivity in oligodendrogliomas. J Neurooncol. 22:1994;1-6.
40. Prayson R.A., Mohan D.S., Song P., Suh J.H. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas. Ann Diagn Pathol. 4:2000;218-227.
41. Reifenberger J., Reifenberger G., Liu L., James C.D., Wechsler W., Collins V.P. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic delations on 19q and 1p. Am J Pathol. 145:1994;1175-1190.
42. Reifenberger J., Ring G.U., Gies U., et al. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol. 55:1996;822-831.
43. Reis-Filho J.S., Faoro L.N., Carrilho C., Bleggi-Torres L.F., Schmitt F.C. Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendroglioma. Cancer. 88:2000;862-869.
44. Reis-Filho J.S., Netto M.R.M., Sluminsky B.G., et al. Oligodendrogliomas. Arq Neuropsiquiatr. 57:(2-A):1999;249-254.
45. Robinson S., Cohen M., Prayson R., Ransohoff R., Tabrizi N., Miller R.H. Constituitive expression of Growth-related Oncogene and its receptor in oligodendrogliomas. Neurosurg. 48:2001;864-874.
46. Russell D.S., Rubinstein L.J. Tumors of central neuroepithelial origin. Russell D.S., Rubinstein L.J., Pathology of Tumours of the Nervous System. 5th edn. 1989;172-187 Williams & Wilkins, Baltimore.
47. Sarkar C., Roy S., Tandon P.N. Oligodendroglial tumors an immunohistochemical and electron microscopic study. Cancer. 61:1988;1862-1866.
48. Sato K., Schauble B., Kleihues P., Ohgaki H. Infrequent alterations of p15, p16, and cyclin D1 genes in non-astrocytic human brain tumors. Int J Cancer. 66:1996;305-308.
49. Schiffer D., Dutto A., Cavalla P., et al. Prognostic factors in oligodendroglioma. Can J Neurol Sci. 24:1997;313-319.
50. Schiffer D., Dutto A., Cavalla P., Chio A., Migheli A., Piva R. Role of apoptosis in the prognosis of oligodendrogliomas. Neurochem Int. 31:1997;245-250.
51. Smith J.S., Jenkins R.B. Genetic alterations in adult diffuse glioma occurrence, significance, and prognostic implications. Frontiers Biosci. 5:2000;213-231.
52. Smith J.S., Perry A., Borell T.J., et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 18:2000;636-645.
53. Taddei G.L., Arganini L., Raspollini M.R., et al. Oligodendroglioma HMB-45 positivity using catalysed signal amplification method: an immunohistochemical (HMB-45, CD31, p53, Mib-1) and ultravascular study. Appl Imunohistochem Molecul Morphol. 9:2001;35-41. [Abstract.].
54. von Deimling A., Louis D.N., von Ammon K., Petersen I., Wiestler O.D., Seizinger B.R. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res. 52:1992;4277-4279.
55. Wharton S.B., Hamilton F.A., Chan W.K., Chan K.K., Anderson J.R. Proliferation and cell death in oligodendrogliomas. Neuropathol Appl Neurobiol. 24:1998;21-28.